

Prevention of Steatosis by Hepatic JNK1

Guadalupe Sabio,^{1,2,5} Julie Cavanagh-Kyros,² Hwi Jin Ko,^{2,4} Dae Young Jung,^{2,4} Susan Gray,² John Y. Jun,⁴ Tamera Barrett,² Alfonso Mora,² Jason K. Kim,^{2,3,4} and Roger J. Davis^{1,2,*}

¹Howard Hughes Medical Institute

²Program in Molecular Medicine

³Department of Medicine, Division of Endocrinology, Metabolism and Diabetes

University of Massachusetts Medical School, Worcester, MA 01605, USA

⁴Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA

⁵Present address: Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología, CSIC, Campus de Cantoblanco-UAM, 28049-Madrid, Spain

*Correspondence: roger.davis@umassmed.edu

DOI 10.1016/j.cmet.2009.09.007

SUMMARY

Nonalcoholic steatosis (fatty liver) is a major cause of liver dysfunction that is associated with insulin resistance and metabolic syndrome. The cJun NH₂-terminal kinase 1 (JNK1) signaling pathway is implicated in the pathogenesis of hepatic steatosis and drugs that target JNK1 may be useful for treatment of this disease. Indeed, mice with defects in JNK1 expression in adipose tissue are protected against hepatic steatosis. Here we report that mice with specific ablation of *Jnk1* in hepatocytes exhibit glucose intolerance, insulin resistance, and hepatic steatosis. JNK1 therefore serves opposing actions in liver and adipose tissue to both promote and prevent hepatic steatosis. This finding has potential implications for the design of JNK1-selective drugs for the treatment of metabolic syndrome.

INTRODUCTION

Nonalcoholic fatty liver disease is the leading cause of liver dysfunction in the non-alcoholic, viral hepatitis-negative, population in the USA and Europe (Angulo and Lindor, 2002; Cortez-Pinto et al., 2006; Skelly et al., 2001). The disease represents a spectrum of liver pathologies, including steatosis, nonalcoholic steatohepatitis, and nonalcoholic cirrhosis. The incidence of nonalcoholic fatty liver disease is associated with obesity, dyslipidemia, insulin resistance, and type 2 diabetes (Anstee and Goldin, 2006). It is likely that this disease represents one aspect of metabolic syndrome (Marchesini et al., 2003; Sanyal, 2002).

The cJun NH₂-terminal kinase 1 (JNK1) signaling pathway is implicated in the pathogenesis of metabolic syndrome (Weston and Davis, 2007). Thus, inhibitory phosphorylation of the adaptor protein IRS1 by JNK1 can cause insulin resistance (Aguirre et al., 2000). Indeed, *Jnk1*^{-/-} mice are protected against insulin resistance caused by feeding a high-fat diet (HFD) (Hirosumi et al., 2002). This observation implicates JNK1 in the regulation of insulin resistance in vivo. However, *Jnk1*^{-/-} mice exhibit resistance to HFD-induced obesity (Hirosumi et al., 2002). It is therefore possible that the effects of JNK1 deficiency on insulin resis-

tance in vivo are a consequence of the failure of HFD-fed *Jnk1*^{-/-} mice to develop obesity. Nevertheless, direct evidence demonstrating a role for JNK1 in the regulation of insulin resistance has been obtained from studies of mice with adipose-specific JNK1 deficiency that exhibit protection against HFD-induced insulin resistance and hepatic steatosis despite normal development of HFD-induced obesity (Sabio et al., 2008).

The liver represents a site of metabolic regulation by JNK1. Indeed, studies using adenoviral delivery of dominant-negative JNK (Nakatani et al., 2004) or *Jnk* shRNA (Yang et al., 2007) to the liver indicate that JNK1 plays an important role in negative regulation of hepatic insulin signaling. Furthermore, *Jnk1*^{-/-} mice fed a methionine and choline-deficient diet are less susceptible to hepatic steatosis (Schattenberg et al., 2006). Moreover, transgenic expression of the MAP kinase phosphatase DUSP-9 in the liver suppresses the activation of MAP kinases, including JNK, and increases insulin sensitivity (Emanuelli et al., 2008). Together, these data indicate that JNK1 plays a critical role in metabolic regulation of the liver. However, it is established that hepatic function, including steatosis and insulin resistance, can be regulated by JNK1 in adipose tissue (Sabio et al., 2008). The relative contribution of JNK1 in hepatocytes to the regulation of HFD-induced hepatic insulin resistance and steatosis is therefore unclear.

The purpose of this study was to test the role of hepatic JNK1. Our approach was to examine the effect of hepatocyte-specific ablation of the *Jnk1* gene in mice. Contrary to expectations, we found that these mice exhibit glucose intolerance, insulin resistance, and hepatic steatosis.

RESULTS AND DISCUSSION

To test the role of JNK1 in the liver, we created mice without (L^{WT}) and with (L^{KO}) selective ablation of the *Jnk1* gene in hepatocytes (Figure 1A). Loss of hepatic JNK1 did not alter the expression of other JNK isoforms (Figure S1). Measurement of JNK activity demonstrated that a high-fat diet (HFD) caused JNK activation in the liver and adipose tissue of control (L^{WT}) mice, but JNK activation was detected only in adipose tissue and not in liver of L^{KO} mice (Figure 1B). A JNK substrate site (Ser307) that negatively regulates insulin receptor substrate (IRS)-1 (Aguirre et al., 2000) exhibited increased phosphorylation in the liver of HFD-fed L^{WT} mice, but not in L^{KO} mice (Figure 1C). Together, these data




Figure 1. Mice with Hepatocyte-Specific Deficiency of JNK1 Are Glucose Intolerant

(A) The liver and quadriceps muscle of *Alb-cre Jnk1^{+/+}* (L^{WT}) mice, *Alb-cre Jnk1^{LoxP/LoxP}* (L^{KO}) mice, and *Jnk1^{-/-}* (KO) mice were examined by immunoblot analysis by probing with antibodies to JNK1 and GAPDH.
 (B) L^{WT} and L^{KO} mice were fed a chow diet (ND) or a high fat diet (HFD) for 16 wks. JNK activity in epididymal (white) fat and liver was measured in a protein kinase (KA) assay using cJun and ATP[γ - ^{32}P] as substrates. The cell extracts used for the protein kinase assay were also examined by immunoblot analysis by probing with an antibody to GAPDH.
 (C) The phosphorylation of IRS1 on Ser-307 in the liver was examined using ND- and HFD- fed L^{WT} and L^{KO} mice by immunoblot analysis by probing with antibodies to IRS1 and phosphoSer-307 IRS1.
 (D) Chow- fed L^{WT} and L^{KO} mice were fasted overnight and administered glucose (2g/kg) by intraperitoneal injection. The activation of AKT in the liver was examined by immunoblot analysis by probing with antibodies to AKT and phosphoAKT.
 (E) Glucose tolerance tests of chow-fed L^{WT} and L^{KO} mice were performed by measurement of blood glucose concentration in animals following intraperitoneal injection of glucose (1g/kg). The data presented represent the mean \pm SD ($n = 10 \sim 15$). Statistically significant differences are indicated (* $p < 0.05$; ** $p < 0.01$).
 (F) Chow- fed L^{WT} and L^{KO} mice were fasted overnight or fed *ad libitum* and the blood glucose concentration was measured (mean \pm SD; $n = 10 \sim 15$). Statistically significant differences are indicated (** $p < 0.01$).

indicate that mice with hepatocyte-specific JNK1 deficiency represent a model for the analysis of the role of JNK1 in the liver.

Hepatocyte-Specific JNK1 Deficiency Causes Glucose Intolerance

We anticipated that L^{KO} mice would exhibit protection against the deleterious effects of diet-induced obesity compared with L^{WT} mice. This expectation was based on previous studies that have established a role for JNK1 as an inhibitor of insulin signal transduction in multiple tissues (Aguirre et al., 2000; Hirosumi et al., 2002; Sabio et al., 2008). Moreover, studies using intravenous administration of adenovirus vectors to interfere with the JNK1 pathway in the liver suggest that hepatic JNK1 negatively regulates insulin signaling in the liver (Nakatani et al., 2004; Yang et al., 2007). In contrast, we found that HFD-fed L^{KO} and L^{WT} mice exhibited similar glucose intolerance (Figure S2A), insulin-

induced decrease in blood glucose levels (Figure S2B), glucose-induced insulin release (Figure S2C), and serum glucose levels (Figures S3B and S3C). Furthermore, hyperinsulinemic-euglycemic clamp studies demonstrated a similar loss of hepatic insulin action in HFD-fed L^{KO} and L^{WT} mice (Figure S3F). These data indicated that JNK1 deficiency in hepatocytes does not protect against diet-induced insulin resistance. Moreover, we found that chow-fed L^{KO} mice exhibited a profound defect in glucose-induced activation of hepatic AKT (Figure 1D), glucose intolerance (Figure 1E), and mild hyperglycemia (Figure 1F).

The observation that mice with hepatocyte-specific ablation of the *Jnk1* gene exhibit glucose intolerance (Figure 1E) contrasts with conclusions of previous studies of hepatic JNK1 that have employed intravenous delivery of adenoviruses that express dominant-negative JNK (Nakatani et al., 2004) or *Jnk* shRNA (Yang et al., 2007). The mechanism that accounts for the

different phenotypes of these mouse models is unclear. One possibility is that these phenotypes reflect the effect of disruption of the JNK1 signaling pathway in different cell types. Thus, *Cre*-mediated ablation of *Jnk1* in hepatocytes may differ from the effect of adenovirus-mediated suppression of JNK1 signaling in multiple hepatic cell types, including hepatocytes, stellate cells, endothelial cells, and innate immune cells (e.g., Kupffer cells and NKT cells). Indeed, studies of murine hepatitis have established that the phenotype of mice with hepatocyte-specific ablation of *Jnk1* markedly differs from mice with ablation of *Jnk1* in multiple hepatic cell types (Das et al., 2009).

Hepatocyte-Specific JNK1 Deficiency Increases Insulin Clearance

The major defect in glucose-induced hepatic insulin signaling observed in chow-fed L^{KO} mice (Figure 1D) may reflect a reduction in the blood concentration of insulin. No significant difference in the fasting blood insulin concentration between L^{KO} and L^{WT} mice was detected (Figure 2A). Morphological analysis demonstrated that the size of pancreatic islets was similar in L^{KO} and L^{WT} mice (Figure S4). Nevertheless, the amount of glucose-induced blood insulin was markedly decreased in L^{KO} mice compared with L^{WT} mice (Figure 2B). This loss of blood insulin could result from decreased insulin secretion or increased insulin clearance. To distinguish between these possible mechanisms, we examined the blood concentration of C-peptide (a proteolytic by-product of insulin processing) that is secreted together with insulin from pancreatic β cells. We found that the fasting C-peptide concentration in the blood of L^{KO} mice was greatly increased compared with L^{WT} mice (Figure 2C). Nevertheless, a similar glucose-induced increase in blood C-peptide concentration was detected in L^{KO} and L^{WT} mice (Figure 2D), suggesting that insulin secretion was not altered in L^{KO} mice. Together, these observations suggest that insulin clearance was increased in L^{KO} mice compared with L^{WT} mice. To test this hypothesis, we injected mice with human insulin and measured the time course of changes in the concentration of human insulin in the blood. This analysis demonstrated that, compared with L^{WT} mice, the peak insulin concentration detected in L^{KO} mice was greatly reduced (Figure 2E). The clearance of blood insulin by L^{KO} mice was also markedly increased compared with L^{WT} mice (Figure 2E). Together, these data indicate that the normal levels of blood insulin detected in fasting L^{KO} mice are due to increased insulin clearance balanced by a compensatory increase in insulin secretion.

The liver is the major site of insulin clearance within the body. Indeed, it is estimated that 50% of insulin newly secreted by pancreatic β cells into the portal vein is internalized and degraded by the liver (Duckworth et al., 1998). Hepatic insulin clearance requires the insulin receptor (Michael et al., 2000) and is regulated by Ceacam1 (Poy et al., 2002). The increased amounts of insulin receptor and Ceacam1 in the liver (Figures 2F and S5) may contribute to the increased insulin clearance in L^{KO} mice (Figure 2E).

Hepatocyte-Specific JNK1 Deficiency Causes Insulin Resistance

To further characterize the metabolic phenotype of chow-fed L^{KO} mice, we performed a hyperinsulinemic-euglycemic clamp study. This analysis demonstrated that L^{KO} mice exhibited

increased hepatic glucose production (HGP) during the clamp and therefore decreased hepatic insulin action compared with L^{WT} mice (Figures 3B and 3C). Indeed, the liver of L^{KO} mice expressed increased amounts of PGC-1 α (Figure S6), a coactivator of the gluconeogenic gene transcription factors HNF4 α and FOXO1 (Puigserver et al., 2003; Yoon et al., 2001). Basal HGP and insulin-stimulated whole-body glucose turnover were not altered in L^{KO} mice (Figures 3A and 3D). The fat and lean mass of L^{WT} and L^{KO} mice were similar (Figures 3E and 3F). Insulin treatment caused similar JNK-independent (Rui et al., 2001) negative feedback phosphorylation of IRS1 on Ser307 in L^{KO} mice compared with L^{WT} mice (Figure 3I). However, decreased hepatic AKT activation was detected in L^{KO} mice compared with L^{WT} mice (Figures 3G and 3H). This reduction in AKT activation was associated with reduced insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS1 (Figure S7). Together, these data demonstrate that hepatic loss of JNK1 causes insulin resistance in liver.

Hepatocyte-Specific JNK1 Deficiency Causes Hepatic Steatosis

The increased insulin clearance and hepatic insulin resistance phenotype of chow-fed L^{KO} mice compared with L^{WT} mice (Figures 2 and 3) is likely to cause profound metabolic consequences. Indeed, we found that chow-fed L^{KO} mice exhibited hepatic steatosis (Figure 4A) associated with increased accumulation of triglyceride (Figure 4B) and increased inflammation (Figure S8) compared with L^{WT} mice. Increased amounts of triglyceride were also detected in the blood of chow-fed L^{KO} mice (Figure S9). In contrast, HFD-fed L^{KO} and L^{WT} mice accumulated a similar amount of triglyceride in liver (Figure S10).

The increased triglyceride accumulation in chow-fed L^{KO} mice could be mediated by increased dietary lipid absorption, decreased fat oxidation, and/or increased lipogenesis. We found no differences between L^{KO} and L^{WT} mice in the respiratory exchange quotient $[V_{CO_2}]/[V_{O_2}]$ (Figure S11) or the intestinal absorption of dietary fat (Figure S12). The L^{KO} mice exhibited increased energy expenditure compared with L^{WT} mice, but no differences in food/water intake or physical activity in L^{KO} mice were detected (Figure S11). These observations do not support a role for increased dietary fat absorption or decreased fat oxidation as a cause of the hepatic steatosis in L^{KO} mice. De novo lipogenesis may therefore contribute to steatosis in L^{KO} mice. Indeed, increased lipogenesis was detected in the liver of chow-fed L^{KO} mice compared with L^{WT} mice (Figure 4C). Moreover, L^{KO} liver exhibited increased expression of genes that promote hepatic lipogenesis (*C/ebp α* , *C/ebp β* , *Pgc-1 β* , *Ppar γ* , and *Srebp1*) and also genes that encode enzymes that contribute to lipogenesis (*Acaca β* , *Acot3*, *Acs1/4*, *Dgat1*, *Fas*, and *Gyk*) and the export of triglyceride from the liver (*Mttp*) (Figure 4E). These changes in gene expression contribute to hepatic steatosis in chow-fed L^{KO} mice compared with L^{WT} mice. Furthermore, the increased expression of *C/ebp β* in the liver of L^{KO} mice may contribute to enhanced insulin clearance by increasing insulin receptor expression (Foti et al., 2003) (Figures 2E and 2F).

Implications

Steatosis is a widespread human disease that can progress to steatohepatitis and liver failure (Angulo and Lindor, 2002;




Figure 2. JNK1 Deficiency in Hepatocytes Increases Insulin Clearance

(A) Chow-fed L^{WT} and L^{KO} mice were fasted overnight. In (A), the concentration of blood insulin was measured (mean ± SD; n = 10). No statistically significant difference between L^{KO} and L^{WT} mice was detected.

(B) The effect of administration of glucose (2 g/kg body mass) by intraperitoneal injection on blood insulin concentration was examined (mean ± SD; n = ~13–15). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.01).

(C) The concentration of insulin C-peptide in the blood was measured (mean ± SD; n = ~10–15). Statistically significant differences between L^{KO} and L^{WT} are indicated (****p < 0.0001).

(D) The effect of administration of glucose (2 g/kg body mass) on insulin C-peptide concentration in the blood was examined (mean ± SD; n = 15). No statistically significant difference between L^{KO} and L^{WT} was detected.

(E) Mice were injected with human insulin (1.5 U/kg body mass). The concentration of human insulin in the blood was measured (mean ± SD; n = 15). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.05).

(F) The expression of the *insulin receptor* (*InsR*), *Caecam-1*, and *Gapdh* mRNA in the liver was measured by quantitative RT-PCR (Taqman) assays. The expression of *insulin receptor* (*InsR*) and *Caecam-1* mRNA was normalized to the amount of 18S RNA in each sample (mean ± SD; n = 7). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.05; ***p < 0.001).

Cortez-Pinto et al., 2006; Skelly et al., 2001). The finding that the loss of JNK1 in hepatocytes causes steatosis identifies a possible complication of drug therapies involving JNK1 inhibition designed to treat insulin resistance. Indeed, the hepatic

insulin resistance caused by hepatocyte-specific ablation of the *Jnk1* gene is associated with increased gluconeogenesis and also increased lipogenesis. This paradox (selective insulin resistance) represents a central characteristic of type 2 diabetes




Figure 3. Mice with JNK1-Deficient Hepatocytes Exhibit Hepatic Insulin Resistance

(A–F) Insulin sensitivity was measured using a hyperinsulinemic-euglycemic clamp in conscious chow-fed L^{KO} and L^{WT} mice. In (A), basal hepatic glucose production (HGP) is shown. In (B), insulin-stimulated rate of HGP is shown. In (C), hepatic insulin action, expressed as insulin-mediated percent suppression of basal HGP is portrayed. In (D), insulin-stimulated whole body glucose turnover is shown. In (E), whole-body fat mass measured using ¹H-MRS is shown. In (F), whole-body lean mass is shown. The data presented are the mean ± SE for ~6–8 experiments. Statistically significant differences between L^{KO} mice and L^{WT} mice are indicated (*p < 0.05).

(G and H) Chow-fed L^{KO} and L^{WT} mice were administered insulin (0.3U/kg body mass) by intravenous injection (5 min). The activation of AKT in the liver was examined by immunoblot analysis by probing with antibodies to AKT and phospho-AKT. The relative amount of phospho-AKT is presented as the mean ± SD (n = 3). Statistically significant differences between L^{KO} and L^{WT} mice are indicated (*p < 0.05).

(I) Chow-fed L^{KO} and L^{WT} mice were administered insulin (0.3U/kg body mass) by intravenous injection (5 min). The phosphorylation of IRS1 on Ser307 in the liver was examined by immunoblot analysis by probing with antibodies to IRS1 and phospho-Ser307 IRS1.

with suppression of the FOXO1 pathway and activation of the SREBP-1 pathway (Brown and Goldstein, 2008). These considerations indicate that hepatocyte-specific JNK1-deficient mice

exhibit the typical features of insulin resistance that are associated with metabolic syndrome. The increased expression of the transcription factor FOXO1, the coactivator PGC-1 α , and




Figure 4. JNK1 Deficiency in Hepatocytes Causes Steatosis

(A) Chow-fed L^{WT} and L^{KO} mice were fasted overnight. Representative sections of the liver stained with oil red O are presented. (B) The amount of hepatic triglyceride was measured in mice fasted overnight (mean ± SD; n = 10). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.05). (C) The amount of hepatic lipogenesis was measured in mice fasted 6 hr (mean ± SD; n = ~8–9). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.05). (D) The expression of genes that encode lipogenic transcription factors and coactivators in the liver of chow-fed L^{KO} and L^{WT} mice that were fasted overnight (*Clebpα*, *Clebpβ*, *Pgc1β*, *Pparγ*, and *Srebp1*) was measured by quantitative RT-PCR assays of the amount of mRNA and was normalized to the amount of 18S RNA in each sample (mean ± SD; n = 7). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.05; **p < 0.01). (E) The expression of genes that encode enzymes that promote lipogenesis in the liver of chow-fed L^{KO} and L^{WT} mice that were fasted overnight (*Fas*, fatty acid synthase; *Acs1/4*, acetyl-CoA synthetase long chain family member 1/4; *Accα/β*, acetyl-CoA carboxylase α/β; *Acot3*, Acetyl-CoA thioesterase; *Dgat1*, Diacylglycerol O-acyltransferase homolog 1; *Glyk*, Glycerol kinase; *Mttp*, microsomal triglyceride transfer protein) was measured by quantitative RT-PCR assays of the amount of mRNA and was normalized to the amount of 18S RNA in each sample (mean ± SD; n = 7). Statistically significant differences between L^{KO} and L^{WT} are indicated (*p < 0.05; **p < 0.01).

gluconeogenic target genes (e.g., *Pepck*) may contribute to gluconeogenesis in L^{KO} mice (Figure S6). The mechanism that accounts for increased lipogenesis is unclear, but it is most likely the result of increased expression of multiple lipogenic genes (Figure 4E) and increased expression of lipogenic transcription factors (e.g., SREBP-1, C/EBPα/β, and PPARγ) and the coactivator PGC-1β (Figure 4D).

Hepatic steatosis is prevented in *Jnk1*^{-/-} mice (Schattenberg et al., 2006). This observation suggests that the metabolic milieu in response to JNK1 deficiency in different organs may compensate for the effects of JNK1 deficiency in hepatocytes. Indeed, JNK1 plays a major regulatory role in adipose tissue leading to protection against HFD-induced hepatic insulin resistance and steatosis (Sabio et al., 2008). This is consistent with the finding that systemic treatment of mice with a JNK inhibitor can protect against the effects of feeding a HFD (Kaneto et al., 2004). However, not all of the deleterious effects of hepatocyte-specific JNK1 deficiency are compensated in *Jnk1*^{-/-} mice, including increased insulin clearance (Figure S13).

The observation that hepatic JNK1 deficiency increases insulin clearance has implications for the use of JNK1 as a drug target for the treatment of metabolic syndrome, including insulin resistance and steatosis. Disease progression from metabolic syndrome to type 2 diabetes is triggered by the failure of pancreatic β cells due to exhaustion (Burks and White, 2001). In this regard, the compensatory increase in insulin secretion in response to enhanced insulin clearance caused by hepatic JNK1 inhibition may have adverse chronic effects on β cell function. The cytoprotective effects of JNK inhibition on β cells (Bonny et al., 2001) may therefore be critical for the design of effective therapies that target JNK1 for the treatment of metabolic syndrome.

EXPERIMENTAL PROCEDURES

Mice

We have described *Jnk1*^{-/-} mice (Dong et al., 1998), *Jnk1*^{fl/fl} mice (Das et al., 2007), and *Jnk2*^{-/-} mice (Yang et al., 1998). *Alb-Cre* mice (Postic et al.,

1999) were obtained from Jackson Laboratory. The mice were backcrossed to the C57BL/6J strain (Jackson Laboratory) and were housed in facilities accredited by the American Association for Laboratory Animal Care (AALAC). All studies were performed using male mice (8–24 weeks old). The mice were genotyped by PCR analysis of genomic DNA (Das et al., 2007). The animal studies were approved by the Institutional Animal Care and Use Committees (IACUC) of the University of Massachusetts Medical School, University of Cincinnati, and Pennsylvania State University College of Medicine.

Immunoblot Analysis

Tissue extracts were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β -glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μ g/mL of aprotinin and leupeptin). Extracts (20–50 μ g of protein) and immunoprecipitates (prepared from 2–10 mg protein) were examined by protein immunoblot analysis. The antibodies employed were the following: AKT, phosphoSer-308 AKT, and phosphoSer-473 AKT (Cell Signaling); IRS1 (Sabio et al., 2008); IRS2, phosphotyrosine, and phospho-Ser³⁰⁷ IRS1 (Millipore); insulin receptor β subunit, JNK1 and GAPDH (Santa Cruz); and JNK1/2 (BD PharMingen). Immunocomplexes were detected by enhanced chemiluminescence (NEN). Quantitation of immunoblots was performed using the Odyssey infrared imaging system (LI-COR Biosciences).

Measurement of Blood Glucose and Insulin Concentration

Blood glucose was measured with an Ascensia Breeze 2 glucose meter (Bayer). Insulin and insulin C-peptide in plasma were measured by ELISA using a Luminex 200 machine (Millipore).

Statistical Analysis

Differences between groups were examined for statistical significance using the Student's test or analysis of variance (ANOVA) with the Fisher's test.

SUPPLEMENTAL DATA

The Supplemental Data include 13 figures, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at [http://www.cell.com/cellmetabolism/supplemental/S1550-4131\(09\)00295-2](http://www.cell.com/cellmetabolism/supplemental/S1550-4131(09)00295-2).

ACKNOWLEDGMENTS

We thank D. Lee and P. Tso for the analysis dietary fat absorption (Mouse Metabolic Phenotyping Center, University of Cincinnati); M. Das for providing the floxed *Jnk1* mice; V. Benoit, J. Reilly, J.-H. Liu, and R. Friedline for expert technical assistance; and K. Gemme for administrative assistance. These studies were supported by grants from the National Institutes of Health (CA65861 to R.J.D. and DK80756 to J.K.K.) and the American Diabetes Association (7-07-RA-80 to J.K.K.). The UMass Mouse Phenotyping Center is supported by the NIDDK Diabetes and Endocrinology Research Center (DK52530). R.J.D. is an Investigator of the Howard Hughes Medical Institute.

Received: June 24, 2009

Revised: August 17, 2009

Accepted: September 25, 2009

Published: December 1, 2009

REFERENCES

Aguirre, V., Uchida, T., Yenush, L., Davis, R.J., and White, M.F. (2000). The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). *J. Biol. Chem.* 275, 9047–9054.

Angulo, P., and Lindor, K.D. (2002). Treatment of non-alcoholic steatohepatitis. *Best Pract. Res. Clin. Gastroenterol.* 16, 797–810.

Anstee, Q.M., and Goldin, R.D. (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. *Int. J. Exp. Pathol.* 87, 1–16.

Bonny, C., Oberson, A., Negri, S., Sauser, C., and Schorderet, D.F. (2001). Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. *Diabetes* 50, 77–82.

Brown, M.S., and Goldstein, J.L. (2008). Selective versus total insulin resistance: a pathogenic paradox. *Cell Metab.* 7, 95–96.

Burks, D.J., and White, M.F. (2001). IRS proteins and beta-cell function. *Diabetes* 50 (Suppl 1), S140–S145.

Cortez-Pinto, H., de Moura, M.C., and Day, C.P. (2006). Non-alcoholic steatohepatitis: from cell biology to clinical practice. *J. Hepatol.* 44, 197–208.

Das, M., Jiang, F., Sluss, H.K., Zhang, C., Shokat, K.M., Flavell, R.A., and Davis, R.J. (2007). Suppression of p53-dependent senescence by the JNK signal transduction pathway. *Proc. Natl. Acad. Sci. USA* 104, 15759–15764.

Das, M., Sabio, G., Jiang, F., Rincon, M., Flavell, R.A., and Davis, R.J. (2009). Induction of hepatitis by JNK-mediated expression of TNF-alpha. *Cell* 136, 249–260.

Dong, C., Yang, D.D., Wysk, M., Whitmarsh, A.J., Davis, R.J., and Flavell, R.A. (1998). Defective T cell differentiation in the absence of Jnk1. *Science* 282, 2092–2095.

Duckworth, W.C., Bennett, R.G., and Hamel, F.G. (1998). Insulin degradation: progress and potential. *Endocr. Rev.* 19, 608–624.

Emanuelli, B., Eberle, D., Suzuki, R., and Kahn, C.R. (2008). Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. *Proc. Natl. Acad. Sci. USA* 105, 3545–3550.

Foti, D., Iuliano, R., Chiefari, E., and Brunetti, A. (2003). A nucleoprotein complex containing Sp1, C/EBP beta, and HMG1-Y controls human insulin receptor gene transcription. *Mol. Cell. Biol.* 23, 2720–2732.

Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M., and Hotamisligil, G.S. (2002). A central role for JNK in obesity and insulin resistance. *Nature* 420, 333–336.

Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T.A., Matsu-hisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y., and Hori, M. (2004). Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. *Nat. Med.* 10, 1128–1132.

Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 37, 917–923.

Michael, M.D., Kulkarni, R.N., Postic, C., Previs, S.F., Shulman, G.I., Magnuson, M.A., and Kahn, C.R. (2000). Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol. Cell* 6, 87–97.

Nakatani, Y., Kaneto, H., Kawamori, D., Hatazaki, M., Miyatsuka, T., Matsuoka, T.A., Kajimoto, Y., Matsu-hisa, M., Yamasaki, Y., and Hori, M. (2004). Modulation of the JNK pathway in liver affects insulin resistance status. *J. Biol. Chem.* 279, 45803–45809.

Postic, C., Shiota, M., Niswender, K.D., Jetton, T.L., Chen, Y., Moates, J.M., Shelton, K.D., Lindner, J., Cherrington, A.D., and Magnuson, M.A. (1999). Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J. Biol. Chem.* 274, 305–315.

Poy, M.N., Yang, Y., Rezaei, K., Fernstrom, M.A., Lee, A.D., Kido, Y., Erickson, S.K., and Najjar, S.M. (2002). CEACAM1 regulates insulin clearance in liver. *Nat. Genet.* 30, 270–276.

Puigserver, P., Rhee, J., Donovan, J., Walkey, C.J., Yoon, J.C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003). Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. *Nature* 423, 550–555.

Rui, L., Aguirre, V., Kim, J.K., Shulman, G.I., Lee, A., Corbould, A., Dunaif, A., and White, M.F. (2001). Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. *J. Clin. Invest.* 107, 181–189.

- Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J.Y., Ko, H.J., Barrett, T., Kim, J.K., and Davis, R.J. (2008). A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science* 322, 1539–1543.
- Sanyal, A.J. (2002). AGA technical review on nonalcoholic fatty liver disease. *Gastroenterology* 123, 1705–1725.
- Schattenberg, J.M., Singh, R., Wang, Y., Lefkowitz, J.H., Rigoli, R.M., Scherer, P.E., and Czaja, M.J. (2006). JNK1 but not JNK2 promotes the development of steatohepatitis in mice. *Hepatology* 43, 163–172.
- Skelly, M.M., James, P.D., and Ryder, S.D. (2001). Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. *J. Hepatol.* 35, 195–199.
- Weston, C.R., and Davis, R.J. (2007). The JNK signal transduction pathway. *Curr. Opin. Cell Biol.* 19, 142–149.
- Yang, D.D., Conze, D., Whitmarsh, A.J., Barrett, T., Davis, R.J., Rincon, M., and Flavell, R.A. (1998). Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. *Immunity* 9, 575–585.
- Yang, R., Wilcox, D.M., Haasch, D.L., Jung, P.M., Nguyen, P.T., Voorbach, M.J., Doktor, S., Brodjian, S., Bush, E.N., Lin, E., et al. (2007). Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. *J. Biol. Chem.* 282, 22765–22774.
- Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C.R., Granner, D.K., et al. (2001). Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 413, 131–138.